Status and phase
Conditions
Treatments
About
Autologous stromal vascular fraction (SVF) injected at 8 and 10 days after extraction is safe and useful procedure in inducing remission of RA in patients resistant to standard DMARD therapy.
Full description
The proposed study will assess primarily safety and secondary efficacy endpoints of autologous stromal vascular fraction (SVF) cells administered to 20 patients with disease modifying antirheumatic drug (DMARD)-resistant Rheumatoid Arthritis (RA) who have been nonresponsive to at least one course of one DMARD selected from a group comprising of: gold salts, leflunomide, methotrexate, and hydroxychloroquine.
The primary objective of safety will be defined as freedom from treatment associated adverse events for the period of one year. The secondary objective of efficacy will include evaluation at baseline and at months 1, 2, 3 and 6 of efficacy endpoints of CRP, ESR, anti-citrulline antibody, RF, Quality of Life Questionnaire, 28-joint disease activity score (DAS28), European League against Rheumatism (EULAR) response criteria and immunological parameters.
Sex
Ages
Volunteers
Inclusion criteria
Age older than 18 years and ability to understand the planned treatment.
Patients of either gender with RA with a duration of 6 to 72 months defined as the presence of at least three of the following criteria: 6 or more painful, 2 or more swollen joints, morning stiffness for at least 45 minutes (on average during the week prior to entry), and an erythrocyte sedimentation rate (ESR) of at least 28 mm.
Nonresponsive to at least one course of one DMARD selected from the group comprising of: gold salts, leflunomide, methotrexate, and hydroxychloroquine.
Second-line agents are discontinued at least 4 weeks prior to entry.
Able to tolerate ALL study procedures
Able to give informed Consent
Negative for HcG with a serum pregnancy test
Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000,
Life expectancy of 6 months or more in the opinion of the investigator
Serum bilirubin, ALT, AST up to 2.5 time the upper level of normal.
Controlled blood pressure (systolic blood pressure ≤140 and a diastolic blood pressure of ≤90 mmHG) and established anti-hypertensive therapy as necessary prior to entry into the study
Patient has received stable, standard medical therapy for at least one month with no new medications to treat the disease introduced in the last month.
Pre-existing condition (e.g. thromboembolic risk, diabetes, hypercholesterolemia) are adequately controlled in the opinion of the investigator
Fertile patients (male and female) must agree to use an appropriate form of contraception while participating in the study.
Exclusion criteria
Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.
History of prior radiation exposure for oncological treatment.
History of Bone Marrow Disorder (especially NHL, MDS)
History of abnormal bleeding or clotting.
History of Liver Cirrhosis.
End stage renal disease (Creatinine ≤ 3.0 mg / dl) and/or dialysis
Active clinical infection being treated by antibiotics before one week enrollment
Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.
History of life-threatening arrhythmias, except if an automated implantable cardioverter defibrillator (AICD) is implanted
Life expectancy <6 months due to concomitant illnesses
Known cancer and undergoing treatment; chemotherapy and/or radiotherapy
Patients receiving treatment with hematopoietic growth factors (e.g., EPO, G-CSF)
Patients who can not stop anticoagulation therapy (warfarin) 72hrs prior to infusion
Patients who can not stop anti-platelet therapy (clopidogrel) 7 days prior infusion Prior admission for substance abuse
Body Mass Index (BMI) of 40 kg/m2 or greater
Patient receiving experimental medication or participating in another clinical study within 30 days of signing the informed consent
In the opinion of the investigator or the sponsor, the patient is unsuitable for cellular therapy
Primary purpose
Allocation
Interventional model
Masking
0 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal